Navigation Links
Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
Date:11/16/2010

hepatotoxic (eg, acetaminophen, certain antibiotics, antiepileptics). Warn patients to avoid acetaminophen containing products while taking CAMBIA. The liver metabolizes almost 100% of diclofenac, and there is insufficient information to support dosing recommendations in patients with hepatic insufficiency. Hepatic effects range from transaminase elevations to liver failure. Discontinue CAMBIA immediately if abnormal liver tests persist or worsen.

NSAIDs can lead to new onset or worsening of preexisting hypertension. Monitor blood pressure closely during therapy. Patients taking ACE inhibitors, thiazides, or loop diuretics may have impaired response to these therapies when taking NSAIDs. Note that fluid retention and edema have been observed in some patients taking NSAIDs. Use CAMBIA with caution in patients with fluid retention or heart failure.

Using CAMBIA with other NSAIDs (eg, aspirin) or with anticoagulants (eg, warfarin) is not advised due to increased risk of serious adverse events, such as GI bleeding. Use with caution in patients with a history of ulcers or GI bleeding. Anemia may occur in patients on NSAIDs. In patients on long-term therapy, check hemoglobin or hematocrit upon any sign or symptom of anemia or blood loss.

NSAIDs, including CAMBIA, can cause serious skin reactions including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which can be fatal. Discontinue use immediately if rash or other signs of local skin reaction occur.

CAMBIA can harm fetuses. Starting at 30 weeks' gestation, pregnant women should avoid CAMBIA and other NSAIDs as premature closure of the ductus arteriosus in the fetus may occur. Use with caution in nursing mothers as it is not known if diclofenac is excreted in human milk.

The most common adverse events in clinical trials with CAMBIA were nausea and dizziness.


'/>"/>
SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
2. US WorldMeds Acquires Solstice Neurosciences
3. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
4. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
5. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
6. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
7. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
8. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
9. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... S.C. , April 23, 2015 Once ... and strengthening our commitment to patient safety. ... the fight against infectious disease. The next ... Medical gas sensors are now mounted in the ... the need to open ceiling tiles potentially releasing dust ...
(Date:4/23/2015)... -- Research Solutions, Inc. (OTCQB: RSSS), a pioneer in providing on-demand ... life science companies, academic institutions, and other research intensive ... th Annual B. Riley & Co. Investor Conference ... Loews Hollywood Hotel in Los Angeles ... scheduled to present on Tuesday, May 12 th ...
(Date:4/23/2015)... AUGUSTA, Ga. , April 23, 2015 /PRNewswire/ ... of medical holography, has made its Voxgram hologram ... just-launched Kickstarter campaign: https://www.kickstarter.com/projects/629071847/holographic-optical-technologies?ref=nav_search ... first consumer product through the campaign, the eight-inch ... a reward, along with its more established, medical-grade ...
Breaking Medicine Technology:BeaconMedaes launches new Zone Valve Box Assembly 2Research Solutions to Present at the 16th Annual B. Riley & Co. Investor Conference on May 12, 2015 2Research Solutions to Present at the 16th Annual B. Riley & Co. Investor Conference on May 12, 2015 3Holographic Optical Technologies Launches Kickstarter, Offering True 3D Holograms 2
... Nov. 12 Zimmer Holdings, Inc. (NYSE: ZMH ; ... $1.0 billion of its senior unsecured notes in an underwritten ... 2019 and $500.0 million of 5.75% notes due 2039. The ... their Treasury benchmark, and the 30-year notes were priced at ...
... new treatment for autism appears to normalize brain function, ... BCIA-EEG. , In addition to high serotonin ... pattern reflecting impaired brain function, particularly in areas of ... bonding. , However, Quantitative EEG,s conducted ...
Cached Medicine Technology:Zimmer Holdings, Inc. Agrees to Sell $1 Billion of Senior Notes 2New Treatment for Autism 'Holds Promise' 2New Treatment for Autism 'Holds Promise' 3
(Date:4/24/2015)... Eastern Star Masonic Home is hosting an Open House to ... from 1:30-3:00 pm. , Residents from Boone and the surrounding ... opening of the new community room. Light refreshments will be ... to anyone who wishes to visit the rest of the ... be available for use by residents of the facility as ...
(Date:4/24/2015)... Buffalo, New York (PRWEB) April 24, 2015 ... has partnered with Allergy and Asthma Network (The Network), ... PURE Solutions will provide news, tips and information ... on The Network’s newly redesigned website. , The goal ... raising awareness about the travel needs of people with ...
(Date:4/24/2015)... 2015 E-Factor Diet claims to be a ... stress and allows people to enjoy food as rapid weight ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... blueprint that Jared used to lose weight, and all the ... included inside. This is a diet for people who are ...
(Date:4/24/2015)... Del Mar, CA (PRWEB) April 24, 2015 ... newest addition to the staff, Jamie Johansen. She will ... practice, including human resources, patient relations, and reporting. Jamie ... spa and cosmetic surgery sector as the new Practice ... Operations at LaserAway and Practice Manager at American Laser ...
(Date:4/23/2015)... 23, 2015 Fitnet , the only ... now, an accurate calorie counter during video exercise, is featured ... Health and Fitness categories in the Apple Watch App Store ... of the Digital age," now allows clients to use it ... only third party app providing accurate calorie burn counter, cardio ...
Breaking Medicine News(10 mins):Health News:PURE Solutions Partners with Allergy and Asthma Network to Provide Allergy Travel Tips 2Health News:E-Factor Diet: Review Examining John Rowley’s Brand New Weight Loss Program Released 2Health News:Fitnet Handpicked as Top Healthy Living App in Apple Watch Store 2Health News:Fitnet Handpicked as Top Healthy Living App in Apple Watch Store 3
... discovered a protein signaling pathway that becomes hyperactivated in human ... be effective in the treatment of human sarcomas. The ... Cancer Cell . A team of researchers led ... and Chairman of the Department of Oncological Sciences at Mount ...
... St. Louis, MO 23 May, 2011 ... and medical information products and services, announced today ... (METI), a leading manufacturer of medical simulation and ... to release a turn-key health care education product ...
... researchers, including a number from the University of North Carolina ... the genome that contribute to the debilitating lung disease that ... provide insight into the causes of the wide variation in ... the way to new diagnostic markers and therapeutic approaches for ...
... the name of an infection that causes a series of reactions ... The problem for both patients and doctors is that the early ... a severe flu or winter vomiting disease. A researcher at Lund ... which shows both whether a patient has sepsis and how serious ...
... SUNDAY, May 22 (HealthDay News) -- New Swedish research ... major cardiovascular complications among patients who have a ... builds on earlier work that was published by the ... That study suggested that Inspra (eplerenone), an aldosterone antagonist, ...
... the Florida campus of The Scripps Research Institute have for ... natural product isolated from the bark of a plant widely ... foundation to develop an effective alternative to commonly prescribed narcotic ... in an advanced online edition of the journal Nature ...
Cached Medicine News:Health News:Mount Sinai researchers discover possible new target for sarcoma treatment and prevention 2Health News:Elsevier and METI collaborate to offer simulation technology for health science curriculums 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 3Health News:Quicker detection and treatment of severe sepsis 2Health News:Blood Pressure Drug Helps Those With Mild Heart Failure 2Health News:Led by advances in chemical synthesis, scientists find natural product shows pain-killing properties 2Health News:Led by advances in chemical synthesis, scientists find natural product shows pain-killing properties 3
... a foldable silicone IOL. It features a ... designed to be inserted with The UNFOLDER® ... is the first and only FDA-approved multifocal ... a full range of functional visionnear, intermediate, ...
... with optimum molecular weight and viscosity, so ... coats and protects the delicate structures of ... balance of cohesion, adhesion, and pseudoplasticity to ... phaco surgeon expects from an ophthalmic viscoelastic ...
... Healon GV is a sterile, non-pyrogenic, ... purified, noninflammatory, high molecular weight (average ... sodium hyaluronate. Healon GV contains 14 ... in a physiological sodium chloride-phosphate buffer ...
... PROVISC ophthalmic viscosurgical device is ... characterized by high molecular weight, ... tension. It provides excellent space ... is easily removed. It is ...
Medicine Products: